Biological Material Clause Samples

The 'Biological Material' clause defines the types of biological substances covered under an agreement, such as cell lines, tissues, or genetic material. It typically outlines how these materials may be used, transferred, or modified by the parties, and may specify requirements for handling, storage, or intellectual property rights associated with the materials. This clause ensures clarity regarding the scope and permitted uses of biological materials, helping to prevent disputes and protect the interests of both providers and recipients.
POPULAR SAMPLE Copied 1 times
Biological Material. 2.3.1. As between the parties hereto, subject to the the terms herein, including without limitation, the license granted to Licensee pursuant to Section 2.1 and any Sublicenses granted to Sublicensees pursuant to Section 2.2, all rights, title and interest in and to all Biological Material, and any intellectual property applying thereto, shall be owned solely and exclusively by Harvard. 2.3.2. Licensee shall not use Biological Material other than in accordance with the rights expressly granted to it hereunder. Except in connection with Sublicenses granted pursuant to Section 2.2, Licensee shall not sell or otherwise transfer any Biological Material to any third party. 2.3.3. The Biological Material is provided only for use in animals or in vitro. THE BIOLOGICAL MATERIAL SHALL NOT BE USED IN HUMANS. 2.3.4. Licensee shall inform Harvard’s Office of Technology Development (at ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇. and ▇▇▇▇▇ ▇. ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇, (▇▇▇) ▇▇▇-▇▇▇▇, Attn: Chief Technology Development Officer) of any Biological Material created by Licensee that is different from, and a modification to, the Biological Material listed in Exhibit 1.3, and upon Harvard’s request, shall provide samples of such material to Harvard. 2.3.5. Licensee shall deliver to Harvard between [XXX] and [XXX] of the product of Licensee’s expansion of the Biological Material, at Licensee’s expense, no later than August 15, 2016. 2.3.6. As between the parties hereto, all right, title and interest in and to all Viruses, Products, and any intellectual property applying thereto or to the production thereof, shall be owned solely and exclusively by Licensee. For the avoidance of doubt, nothing herein prohibits or is intended to prohibit the use of Products in humans.
Biological Material. Umbilical Cord Blood or Placental Blood of the Child containing Stem Cells;
Biological Material. As used in this Agreement, “Biological Material” means Institute’s rights in vectors, constructs, cells, plasmids and/or other biological materials owned or controlled (with the right to sublicense) by Institute and first made in the performance of the Research under a Research Plan.
Biological Material. Any Biological Material made available to a party ("Receiving Party") by the other party ("Delivering Party") is made available for research purposes within the Program only and shall not be used for any other purpose without the prior written consent of the Delivering Party. Biological Material provided hereunder will not be used for experiments in which human beings are subjected to the Biological Material, nor for research purposes other than the Program, for third parties, nor will Biological Material be transferred to any party outside the Receiving Party without the prior written consent of the Delivering Party. The Receiving Party obtains no rights or license in the transferred Biological Material nor may the Receiving Party file any patent applications claiming such Biological Material without the Delivering Party's prior consent. The Receiving Party will handle such Biological Material in compliance with all laws, regulations and guidelines applicable to the Biological Material and its use. The Biological Material is experimental in nature, and is provided AS IS without any warranties with respect to performance or fitness for particular purpose, or to completeness and accuracy of information accompanying the Biological Material. The Receiving Party acknowledges that the Biological Material is provided AS IS and without any representation or warranty, express or implied unless otherwise agreed by the Parties.
Biological Material shall supply KeyGene with the Biological Material in the quantities mutually agreed upon by KeyGene and XXII as set out in the applicable PAS and on the delivery date as set out in the applicable PAS. XXII acknowledges that KeyGene can only start with the execution of its activities under the Project(s) once it has received the Biological Material and associated XXII Background that it requires to conduct its activities under the Project(s).
Biological Material. Upon termination of this Agreement, whether by Lilly or Versicor, Versicor shall cease all use of any Biological Materials and shall, upon request, return or destroy (at Lilly's option) all Biological Materials under its control or in its possession within sixty (60) days and provide a written warranty by an Officer of Versicor that the Biological Materials have been returned or destroyed.
Biological Material please check all that applyIf applicable, submit a new MUA/registration or an amendment to your existing MUA/registration   Human Product: cell lines, tissue, and/or fluids Answer Section II-Question 5a Provide Human Products Registration and/or Biosafety number:   Animal product: cell lines, tissue and/or fluids Provide Animal Sample Registration:   rDNA or synthetic nucleic acid molecules Provide Biosafety approval number:   Microorganisms Provide Biosafety number:   Biological Toxin or Select Agents (▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/SelectAgentsandToxinsList.html) Provide Biosafety number:   Other:  
Biological Material. “Biological Material” shall mean Dow proprietary strains of transformed Pseudomonas fluorescens genetically engineered to express Product. It includes Dow proprietary strains of Pseudomonas fluorescens, Dow proprietary plasmids and expression vectors for transforming Pseudomonas fluorescens, Dow proprietary nucleic acid and protein based probes relating to genetic transformation of Pseudomonas fluorescens, and Dow proprietary plasmids and expression vectors for transforming Pseudomonas fluorescens to express Product, and Dow proprietary nucleic acid and protein based probes relating to genetic transformation of Pseudomonas fluorescens that express Product.
Biological Material. 2.3.1 Exhibit 2.3.1 lists the GCOR Biological Materials. 2.3.2 On Exhibit 2.3.1 INNX has indicated those GCOR Biological Materials which INNX has elected to have transferred to INNX (the *** TEXT OMITTED AND FILED SEPARATELY CONFIDENTIAL TREATMENT REQUESTED "Elected Biological Materials") and those Elected Biological Materials that form part of the Tier 1 Transferred Rights.
Biological Material. The following Biological Material is provided by the BRK Blood Bank to the Client: Case group: blood donors diagnosed with colorectal, breast, liver, prostate, kidney, and pancreatic cancer Control group: blood donors without known pathogenesis, self-declared by the donor Number of cases: 60 individuals [36-67/ M and F] lN/Tntexvi a l P v o b a n a o f i V-\xr a n d F-\¿r*t-▇▇ ▇ .n U P 1 7 R lrxz-vrl R n n L ' a n z - l T Tr->it r -rc -it r /'■'if D a r H n K i p a page 7 of 8 Number of controls: • 24 individuals Sample specification Sample number per donor: 3-4. collected within 36 months before diagnosis Sample volume: 125 ul each, provided in 1.5 ml tubes, labelled with a code specifying case/control and a project specific pseudonymous identifier Sample quality: collection and storage according to BRK Blood Bank SOPs. 1 freeze/thaw/freeze cycle Shipment conditions: courier delivery to an address in Czechia specified by the Client, shipment on dry ice Quality Controls: sample handling is performed by trained laboratory staff; sample labelling is cross-checked by a second trained lab technician